Home › Compare › IMVIF vs XYLD

IMVIF vs XYLD: Dividend Comparison 2026

IMVIF yields 20000000.00% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMVIF wins by $4.875981653489057e+49M in total portfolio value
10 years
IMVIF
IMVIF
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875981653489057e+49M
Annual income
$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full IMVIF calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — IMVIF vs XYLD

📍 IMVIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMVIFXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMVIF + XYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IMVIF pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMVIF
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, IMVIF beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMVIF + XYLD for your $10,000?

IMVIF: 50%XYLD: 50%
100% XYLD50/50100% IMVIF
Portfolio after 10yr
$2.4379908267445285e+49M
Annual income
$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMVIF buys
0
XYLD buys
0
No recent congressional trades found for IMVIF or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMVIFXYLD
Forward yield20000000.00% ✓10.98%
Annual dividend / share$2.00$4.30 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.875981653489057e+49M$25.3K ✓
Annual income after 10y$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$3,219.02
Total dividends collected$4.875978515990276e+49M$19.6K ✓
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: IMVIF vs XYLD ($10,000, DRIP)

YearIMVIF PortfolioIMVIF Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$2,000,010,700$2,000,000,000.00$10,818$1,098.39+$2000.00M → IMVIF
2$373,835,915,712,384$373,833,775,700,934.50$11,738$1,222.51+$373835915.70M → IMVIF
3$65,304,953,364,964,970,000$65,304,553,360,535,160,000.00$12,774$1,364.64+$65304953364964.95M → IMVIF
4$10,661,728,832,755,500,000,000,000$10,661,658,956,455,399,000,000,000.00$13,944$1,527.86+$10661728832755499008.00M → IMVIF
5$1,626,767,783,781,495,000,000,000,000,000$1,626,756,375,731,643,800,000,000,000,000.00$15,270$1,715.87+$1.626767783781495e+24M → IMVIF
6$231,974,330,054,625,100,000,000,000,000,000,000$231,972,589,413,096,470,000,000,000,000,000,000.00$16,775$1,933.09+$2.319743300546251e+29M → IMVIF
7$30,915,106,403,922,057,000,000,000,000,000,000,000,000$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00$18,490$2,184.87+$3.0915106403922057e+34M → IMVIF
8$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00$20,450$2,477.63+$3.8505079858392777e+39M → IMVIF
9$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00$22,697$2,819.19+$4.4821026103531426e+44M → IMVIF
10$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$25,280$3,219.02+$4.875981653489057e+49M → IMVIF

IMVIF vs XYLD: Complete Analysis 2026

IMVIF — Stock

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Full IMVIF Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this IMVIF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMVIF vs SCHDIMVIF vs JEPIIMVIF vs OIMVIF vs KOIMVIF vs MAINIMVIF vs QYLDIMVIF vs JEPQIMVIF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.